Investor Presentaiton

Performance: 2022 free cash flow of £3.3bn¹ 2022 cash generated from operations of £7.9bn¹ Key dynamics Higher cash generated from operations, including: ↑ ↑ ↑ - Increased adj. operating profit - Upfront income from Gilead Science, Inc. settlement Favourable foreign exchange ↓ ↓ 2021 free cash flow 3,301 Higher CGFO² Higher taxation paid - Favourable timing of collections - Unfavourable timing of profit share payments for Xevudy sales Higher net Capex³ - Increased cash contributions to UK defined benefit pension schemes - Increased contingent consideration payments Higher increase in inventory Higher taxation payments ⇓ Lower disposal proceeds Other4 275 2022 free cash flow 3,348 1. GSK continuing operations only 2. Cash generated from operations, including changes in working capital, Significant Legal payments and operating contingent consideration liability 3. Net Capex includes purchases less disposals of property, plant and equipment and intangibles 4. Other includes net interest paid, income from associates and JVs and dividends to Non-Controlling Interests GSK 695 3 35 338 All figures in chart in £m 24 24

View entire presentation